Radiation-induced maculopathy and fluocinolone acetonide implant.

Purpose: This study evaluates the effectiveness of fluocinolone acetonide (FAc) implants in managing radiation maculopathy, a complication of ocular irradiation. The primary outcomes were the change in best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and the impact on therapeutic burden and intraocular pressure (IOP).

Methods: This was a retrospective, multicenter, observational study conducted across three French oncology-ophthalmology reference centers.

Efficacy and safety of multiple fluocinolone acetonide implants in diabetic macular oedema: comparison between first and second intravitreal injections.

Purpose: To compare the efficacy and safety between a first and a second injection of fluocinolone acetonide implants (FAc-I) in the treatment of diabetic macular oedema (DMO).

Methods: This retrospective, multicentre cohort study included eyes with chronic DMO that received two consecutive FAc-I injections. We analysed visual and anatomical outcomes, additional DMO treatments, and intraocular pressure (IOP)-related adverse events.

Intrascleral Tunnel Clamping of Fluocinolone Acetonide Implant: A Novel Scleral Fixation Technique.

This retrospective observational study evaluates the efficacy and safety of a novel scleral fixation technique of the fluocinolone acetonide (FAc) implant in four consecutive patients with post-surgical macular edema (PSME). Four patients with PSME underwent intrascleral tunnel clamping (ITC) of the FAc implant due to lens defects. A 25-gauge sclerotomy was made 3.

Effectiveness of dynamic phototherapy in the management of telangiectatic capillaries: A case series.

PurposeTelangiectatic capillaries (TelCaps) are large capillary microaneurysms that can be found in diabetic patients. Focal laser photocoagulation is the standard treatment for these lesions. In case of a lesion too close to the fovea, there is a risk of central scotoma and conventional laser should not be used.

Optical Coherence Tomography of a Folded Amniotic Membrane over a Macular Hole.

Introduction: Placental-derived amniotic membranes (AM) can be used for both macular holes (MHs) and corneal defects. Here, we present a short report of a recurrent full thickness MH treated with a folded AM graft.

Case Presentation: Best corrected visual acuity improved from 35 letters after MH recurrence to 55 letters after second surgery.

Corticosteroids with or without Conventional Disease-Modifying Antirheumatic Drug as First-Line Therapy in Nonanterior Sarcoidosis Uveitis.

Purpose: Sarcoidosis is one of the leading causes of noninfectious uveitis. Systemic immunosuppressive treatment is required in 45% to 70% of patients for severe intermediate or posterior uveitis, and relapses are frequent (30%-60%) during follow-up. We aimed to compare the efficacy and safety of systemic corticosteroid therapy alone versus corticosteroid plus conventional disease-modifying antirheumatic drugs (C-DMARDs) as first-line therapy in patients with nonanterior sarcoidosis uveitis.

Comparative Effectiveness of Intravenous versus Subcutaneous Tocilizumab for Refractory Uveitis: A Retrospective Analysis.

Purpose: To compare the efficacy and safety of IV and subcutaneous tocilizumab in the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis.

Design: Multicenter, retrospective, observational study.

Participants: Adult patients with noninfectious uveitis treated with tocilizumab.

Comparison of Fundus Autofluorescence and Indocyanine Green Angiography in Multiple Evanescent White Dot Syndrome.

Purpose: The aim of this study was to compare fundus blue autofluorescence (BAF) images, indicating photoreceptor alteration, and indocyanine green angiography (ICGA), indicating retinal pigment epithelium (RPE) alteration, in multiple evanescent white dot syndrome (MEWDS) to investigate the initial damage location within the RPE-photoreceptor complex.

Design: Multicentric retrospective cohort study carried out across tertiary centers for retinal and inflammatory diseases in France.

Participants: A total of 31 eyes affected by primary MEWDS were included.

[Monogenic autoinflammatory uveitis].

Monogenic autoinflammatory uveitis belongs to the spectrum of monogenic autoinflammatory diseases. When early-onset uveitis is associated with specific extra-ocular manifestations, particularly in a familial or geographical context, it guides the clinician towards a diagnosis of a monogenic autoinflammatory disease. The clinical presentation and mode of inheritance will help identify the underlying cause, and the detection of a pathogenic variant will confirm the diagnosis and guide the management approach.

What have we learned from a decade treating patients with diabetic macular oedema with 0.19 mg fluocinolone acetonide intravitreal implant?

Diabetic macular oedema [DMO] is a prevalent and sight-threatening condition among diabetic patients, which can cause irreversible blindness. Since angiogenesis and inflammation are two key elements in the etiopathogenesis of DMO, intravitreal injections of vascular endothelial growth factor inhibitors [anti-VEGF] and sustained released intravitreal corticosteroid implants are currently considered as treatments of choice. The introduction, 10 years ago, of the 0.

Neural networks for predicting etiological diagnosis of uveitis.

Background/objectives: The large number and heterogeneity of causes of uveitis make the etiological diagnosis a complex task. The clinician must consider all the information concerning the ophthalmological and extra-ophthalmological features of the patient. Diagnostic machine learning algorithms have been developed and provide a correct diagnosis in one-half to three-quarters of cases.

Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.

Introduction: Neovascular age-related macular degeneration is a global public-health concern, associated with a considerable burden to individuals, healthcare systems, and society. The objective of this study was to understand different perspectives on the challenges associated with the clinical management of neovascular age-related macular degeneration, which could elucidate measures to comprehensively improve clinical care and outcomes.

Methods: A survey was carried out of patients with neovascular age-related macular degeneration, their providers, and clinic staff in 77 clinics across 24 countries on six continents, from a diverse range of healthcare systems, settings, and reimbursement models.

Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey of Patients, Healthcare Providers, and Clinic Staff.

Introduction: In contrast with patients receiving therapy for retinal disease during clinical trials, those treated in routine clinical practice experience various challenges (including administrative, clinic, social, and patient-related factors) that can often result in high patient and clinic burden, and contribute to suboptimal visual outcomes. The objective of this study was to understand the challenges associated with clinical management of diabetic macular edema from the perspectives of patients, healthcare providers, and clinic staff, and identify opportunities to improve eye care for people with diabetes.

Methods: We conducted a survey of patients with diabetic macular edema, providers, and clinic staff in 78 clinics across 24 countries on six continents, representing a diverse range of individuals, healthcare systems, settings, and reimbursement models.

Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.

Introduction: New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.

Methods: This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK.

Refractive outcomes for secondary sutureless posterior chamber lens implantation: sutureless scleral fixating lens Carlevale® versus retropupillary iris-claw lens Artisan®.

Purpose: To compare refractive outcomes of the foldable intraocular lens sutureless scleral fixated sutureless (Carlevale® FIL-SSF) with the iris-claw lens (Artisan®).

Methods: This retrospective study included consecutive patients who underwent a FIL-SSF implantation or an iris-claw implantation between January 2020 and November 2022 in the ophthalmology departments of Hospices Civils de Lyon (France).

Results: A total of 271 eyes from 265 patients were included: 96 eyes in the FIL-SSF group and 175 eyes in the iris-claw group.

Subretinal fibrosis occurrence according to macular neovascularisation subtypes in neovascular age-related macular degeneration.

Purpose: To assess subretinal fibrosis (SF) occurrence in neovascular age-related macular degeneration (nAMD), according to macular neovascularisation (MNV) subtypes.

Methods: A Retrospective national multi centre cohort study included eyes with naive nAMD. Main outcome measures were, according to MNV subtypes, cumulative incidence for SF, risk factors, and best corrected visual acuity (BCVA) for 36 months.

INTEREST OF REGULAR ASSAYS OF AQUEOUS HUMOR INTERLEUKIN-10 LEVELS IN MONITORING OF VITREORETINAL LYMPHOMA.

Purpose: To investigate the variation of interleukin-10 (IL-10) levels in the aqueous humor (AH) of patients with vitreoretinal lymphoma (VRL) throughout therapy and follow-up and analyze the relation of these variations with VRL clinical course and relapse.

Methods: This study retrospectively included consecutive patients diagnosed with VRL in a single center. AH IL-10 samples and patient clinical course were evaluated.

Pro Re Nata brolucizumab for early onset and treatment-naïve diabetic macular edema: A prospective study.

ObjectivesTo determine the efficacy and safety of brolucizumab therapy administered on a (PRN) basis without loading dose in treatment naïve patients with diabetic macular edema (DME) for 1 year follow-up.MethodsPatients with recent DME (<6 months) received a mandatory brolucizumab injection at inclusion and other injections could be given on a PRN basis with an 8-week interval (between injections) at minimum. Rescue therapy with other anti-VEGF was possible in case of incomplete DME resolution after the second brolucizumab with a minimum of 1-month treatment free interval between 2 injections.